MedCity News November 18, 2021
The Food and Drug Administration granted the company de novo clearance for its VR programs to help reduce chronic lower back pain. AppliedVR’s eight-week program is based on cognitive behavioral therapy.
The Food and Drug Administration (FDA) cleared a VR-based platform intended to treat chronic lower back pain. On Tuesday, it cleared AppliedVR’s EaseVRx platform, to help reduce pain in adults ages 18 and older.
It would be AppliedVR’s first FDA cleared product since it was founded in 2015. The Los Angeles-based company started by bringing VR headsets to patients in hospitals, to provide a welcome respite from the noise and stress of hospitals. But then it turned its focus to building tools people could use at home.
The eight-week...
Today's Sponsors
Today's Sponsor